Hello, and welcome to the Danimer Scientific Fourth Quarter and Full Year 2020 Conference Call. Currently, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Russ Zukowski, Vice President of Corporate Finance. Thank you. You may begin.

Thank you, Shumail, and thank you, everyone for joining us today for our fourth quarter and full year 2020 earnings call. Hosting the call today are Danimer's CEO, Steve Croskrey, and CFO, John Dowdy. Phil Van Trump, our Chief Science and Technology Officer is also on the line for questions and answer. During our discussion today, we will be referring to our earnings presentation, which is available on the Investor Relations section of our website at danimerscientific.com. On Slide 2, please note that we may discuss forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include among other things, future results of operations, capacity of production and demand levels that could differ in a material way from those expressed or implied in the forward-looking statements. We assume no obligation to update any forward-looking statements for reflect events or circumstances after the date hereof, except as required by law. Today's presentation also includes references to non-GAAP financial measures. A reconciliation to the most comparable GAAP financial measure can be found in the investor presentation. I will now turn the call over to Steve, who will begin on Slide 3.

Thank you, Russ. Good afternoon, everyone. Before we get started, I want to express my appreciation to our team for their strong execution, as well as to our new shareholders for their exceptional support. During 2020, we completed construction of the world's first commercial PHA facility, and went through a rigorous destocking process all during a pandemic, while simultaneously negotiating development agreements with Mars and Bacardi. Thank you for your hard work, dedication and support. I will start with a review of our business highlights. Following that, I will turn it over to our Chief Financial Officer, John Dowdy, who will provide financial highlights from the fourth quarter and full year 2020. I will then wrap up with some exciting updates on our growth strategy. I'm extremely pleased with our numerous accomplishments during 2020 to end the year with an outstanding customer base, and an unrivaled commercial scale bioplastic technology platform. Becoming public was an important milestone for our company, providing us with additional financial flexibility to achieve our long-term expansion objectives. 2020 was a year of record revenues for Danimer, and we are still in the early stages of an immense opportunity to grow our business and build long-term shareholder value. On today's call, we are going to address four key takeaways. First, the depth and capabilities of our high growth next generation eco tech company that produces 100% biodegradable polymers for use in plastic applications. Second, our massive addressable market spending 500 billion pounds. Third, our unrivaled growth potential from intense demand by blue chip multinational customers. And finally, the progress we have made to significantly expand our business to meet customer demand. Moving to Slide 4, those of you who met us during our SPAC merger transaction, know that we view PHA as the best end of life solution for single use plastics, and that there are no other marine degradable materials available today, with PHA's performance characteristics. We are even more bullish about PHA, now that we are even more bullish now about PHA than we were a few months ago. The tremendous demand resulting from the powerful tailwinds of corporate sustainability commitments, governmental regulation and consumer awareness of the environmental impact of plastic waste is expected to only make our future brighter. We are in a very unique place within our industry that sets us apart from peers. We have the market knowhow, a large portfolio of patents developed over the past 13-years, commercial scale and long-term customer contracts, all of which puts us well ahead of our industry. We have already built our first commercial scale production facility, and we have a significant pipeline of new capacity to extend our leadership position. We have aligned the majority of our expansion plans based on long-term partnerships with customers. Our customers are mainly major blue chip multinational brands that have all made long-term commitments to make their plastic packaging recyclable, reusable or biodegradable. With bioplastics representing less than 1% of the addressable market today, we have only scratched the surface of what we believe to be the immense upside moving forward. Our team is comprised of acknowledged leaders in the bioplastic space, and I could not be more pleased with their measurable achievements at Danimer and in this industry. On the next several slides, I'll provide some context to address some questions that we get on PHA and Danimer's proprietary approach. Turning to Slide 5, Danimer's Nodax PHA is certified as marine degradable by TUV Austria. I'll give you some context on why that is positive for customers and the environment. The two questions we think about with respect to polymers for plastic are is it renewable and what happens at the end of its life. Fossil fuels are non-renewable and typically accumulate in landfills and in nature. Most biopolymers though go away, and those that do can obtain industry certifications for five different environments. Industrially compostable is the easiest standard to achieve, but requires the high heat and moisture of an industrial compost facility. Home compostable is similar, but requires less heat and moisture. So degradable does not require heat or moisture as the polymer is broken down enzymatically by bacteria. Fresh water and finally marine degradable certification such as those Nodax has received are the most difficult and highest standards to achieve, because there is less bacteria in those environments, and so more difficult to degrade. On Slide 6, we show the life cycle of PHA. We make PHA by feeding canola oil to bacteria. The bacteria then convert the carbon from the canola oil into another form of carbon for their own metabolic process, that's PHA. The resulting product is the bioplastic resin that we turn into a finished product. The product is not degraded in your home or on your shelves, but after it is discarded it will be enzymatically degraded by bacteria, as this is their preferred energy source. We believe our PHA is beginning through end of lifecycle puts us at the forefront of sustainability. Moving to Slide 7, we're excited about our PHA leadership position in a significantly large addressable market. It's an 800 billion pounds total market and today virtually all that ends up accumulating in landfills or nature. Even recycled products have to be discarded at some point. Bioplastics, particularly PHA are a viable end of life solution to truly address the growing need to reverse the global plastics crisis. We think bioplastics can replace about 500 billion pounds of the total market, and so far I've only achieved less than 1% of that figure. To put that into perspective, Danimer has announced plans to have 315 million pounds of nameplate production capacity by 2024. That makes us by far the largest producer of PHA globally, and that still pales in comparison to the over 200 billion pounds discarded in nature, 200 billion pounds of fossil fuel based plastics, discarded in nature, including the 17 billion pounds of plastic dumped into the ocean every year that don't make their way into landfills. On Slide 8, we have a long journey that we believe puts us significantly -- we have had a long journey that we believe puts us significantly ahead of our industry in terms of patents, commercial scale production, and long-term commitments from customers. This has made us a pioneer and a world leader in producing natural biopolymers that are biodegradable and compostable. We have grown alongside our customers as partners in our mission to address the global plastic crisis. Their long-term contracts and commitments with us continue to fund our R&D efforts, capacity build out and revolutionary products. This history of continuous innovation has brought us to this current inflection point. Now, as a better capitalized company, we plan to accelerate our growth trajectory and further invest in capabilities to support this growth. We have continued to build out our R&D, engineering, sales and marketing teams to prepare for the expected ramp up in production. We have hired a number of highly experienced leaders in engineering, manufacturing, technology development and finance in support of this growth. We have entered into new partnerships, including our March announcement of a two-year partnership with Mars to develop biodegradable packaging as part of their supply chain. We entered into an agreement with Bacardi to make a biodegradable and compostable spirits bottles to help Bacardi replace 80 million plastic bottles. And more recently, we announced that we intend to double the size of our planned Greenfield facility to further capture the growing demand from customers. I'll now turn it over to John for an update on our financial results.

Thank you, Steve. I'll speak to Slide 9, given the early stages of our trajectory, I'll focus my comments today on the full year 2020 results, the fourth quarter context as applicable, followed by some color on 2021. Revenues for the full year 2020, grew 46% to $47.3 million, compared to $32.3 million in the prior year. This increase was driven by higher sales of our legacy PLA based resins, as well as significant sales of PHA based resins, as we commenced to scale up of commercial PHA production beginning in March of last year. Year-over-year growth of 38% and the fourth quarter was more modest compared to the full year. This accelerating PLA based resin sales earlier in the year as customer saw to increase inventory levels in order to prevent potential supply chain disruptions from the pandemic. As a result, today [ph] that we are currently producing PHA based resins out of our Kentucky facility, having recently completed the first of a two phase expansion for PHA production. Phase 1 added 20 million pounds of finished product nameplate production capacity with fermentation around starting in March 2020, at the same time, the pandemic related lockdowns began. Phase 2 construction has commenced in December. Phase two construction has commenced in December of 2020, and is expected to add an additional 45 million pounds of finished product nameplate capacity in the second quarter of 2022, with production ramping up thereafter. The completion of both phases will bring our total nameplate PHA capacity up to 65 million pounds of finished product per year. In 2020, we derive 10% of our revenues from sales the PHA based resins, a significant increase compared to 1% in 2019. In the fourth quarter PHA based resins climbed to 19% of sales reflecting our expanded production capabilities. Full year gross profit increased to $11.5 million compared to $11.1 million in the prior year. Adjusted gross profit which excludes depreciation, stock based compensation and rent related to our manufacturing operations increased to $16.6 million compared to $14 million in the prior year, driven by higher revenues. On a margin basis, adjusted gross profit was 35.1% compared to 43.2% in the prior year, primarily the result of having limited PHA manufacturing activities in 2020, and incurring incremental costs associated with ramp up and efficiencies. R&D and SG&A expenses excluding depreciation and amortization, stock-based compensation, rent and one-time items were $16.3 million, compared to $12.5 million in the prior year, mainly attributable to an increase in headcount and salaries to support R&D efforts and our future expansion plans. The adjusted EBITDA loss was $3.2 million, as compared to a loss of $1.6 million in the prior year, with a slight increase in gross profit, more than offset by the higher operating expenses. Adjusted EBITDA excludes top base comp, other income and other add bags as reconciled in the Appendix. Adjusted EBITDAR was $402,000 in 2020, compared to $1.5 million in 2019. We are separating out rent as rent expense was primarily related to a sale leaseback agreement associated with the Kentucky facility. Turning to Slide 10, we'll look at 2021, I'll provide several items to keep in mind. Increased availability from the completed Phase 1 capacity expansion will provide for a significant ramp up in revenue for 2021. We expect adjusted EBITDA and cash flow from operations in 2021, as the Kentucky Phase 1 facility ramps up utilization levels from approximately 50% at the beginning of the year, to fully ramp at the end of the year. Noting however, that we are planning a turnaround in Kentucky in the latter part of the second quarter of 2021, the bottleneck and accelerate ramp up. As I noted earlier, the Phase 2 expansion is now expected to be completed in the second quarter of 2022, compared to our initial assumption of late 2021, resulting from the shift and timing of our closing the public company transaction. Total operating costs are expected to be approximately $27 million for 2021, excluding depreciation and amortization, stock based compensation and one-time items. In addition, we expect zero cash taxes due to the significant NOLs, the company has available. For the full year of 2021, we anticipate capital expenditures to be in the range of $100 million to $125 million, primarily to invest into planned capacity expansions. Now I'll turn the call back to Steve.

Thank you, John. Please turn to Slide 11, we have seen customer demand grow as our blue chip multinational customers develop more sustainable products made from bioplastics. It's important to highlight that the growing plastic waste market does more than just increase our addressable market, it also pushes customers to adopt the best solutions amongst plastic alternatives. We therefore continue to experience intense demand and accelerating growth for our marine degradable PHA products. As you can see here, we have a mix of very tenured customer partnerships with major consumer packaging brands, such as Pepsi and Nestle. The recent announcements of partnerships with Bacardi and Mars among others are a testament to the growing appeal of our PHA as a solution to plastic waste. On Slide 12, I'll spend a moment on our growth strategy, which has two primary financial objectives, accelerate our top-line growth and expand our adjusted EBITDA margins. Our growth strategy is comprised of three elements. First, expanding our market share by developing products in partnership with customers to grow demand. We're working on improved versions of our existing products and are currently in the process of filing several new patent applications. Second, de-risking our growth strategy by securing multiyear purchase commitments work contracts to have the customer demand in place, before beginning production. Three, finally attaining favorable unit economics. This includes putting contracts to place that are mutually beneficial to Danimer and customers, as well as approaching expansion decisions with a focus on returns that are well above our costs of capital. So that should be finally as a third bullet attaining favorable unit economics. Based on all these objectives, we are accelerating and increasing our announced expansion plans. The timing and size of future expansions will follow that similar framework. To that point on Slide 13, we are moving toward a bioplastic world even faster than we projected six months ago. Considering that we have announced our intention to double the size of our planned Greenfield facility to catch up with demand, we have chosen Bainbridge, Georgia based on a detailed site selection process. Our plan is now to increase the anticipated Greenfield capacity from 125 million to 250 million pounds nameplates finished of product annually. The new state of the art facility is currently in the preconstruction engineering stage. It is expected to break ground in 2022, with the first-half of the project coming online in mid-2023, and the second-half operational in 2024. The cost of the facility is now projected to be around $700 million, which incorporates the doubling of the facility plus additional enhancements for efficiency. The unit economics remained very attractive on this larger scale. Upon completion, we will be in a much better position to serve our growing order commitments from customers. Moving to Slide 14, even with the planned doubling of the facility, we continue to forecast that the Greenfield plant will be sold out. In fact, based on our conversations with customers and the trends we are seeing in the business, we believe that the market demand and unit economics support additional capacity more than 250 million pounds of finished product per year beyond currently announced capacity additions. We expect our expansion plans to bring considerable benefits to Danimer in coming years, as we reduced lead times and costs, serve more customers concurrently, and leverage the operational infrastructure that we are putting in place today. As you can tell, we have been very busy. PHA demand is growing rapidly. Our products are winning with customers and we're laying the foundation to accelerate growth. We couldn't be more excited with our leading position to deliver a dramatic solution to the global crisis of plastic waste. I will wrap up with the four simple reasons why we were excited for '21 and beyond. We believe our high growth next generation 100% biodegradable plastics have no match. We are on our way to tapping the 500 billion pound market opportunity, of which only 1% is currently served by bioplastics. Our unrivaled growth potential from blue chip customer demand is intensifying. We are accelerating our investments to significantly expand our business supported by customer commitments. We are at an exceptional point in our company's history, and I cannot be more optimistic about our growth prospects in coming years. Thank you for your time today. We'll now open up the line for questions.

At this time, we'll be conducting a question-and-answer session. [Operator Instructions] Our first question is from Jon Tanwanteng with CJS Securities. Please proceed with your question.

Good afternoon, everybody. Thank you for taking my questions. And congratulations on your first quarter as a public company.

Thank you, Jon.

And it's also great to see the demand that you've been talking about increase. My first question, I guess is, can you provide an updated expectation in terms of the profitability you're expecting, compared to what you had in your investor deck last fall? Given your new growth and expansion plans, and what looks like a significant inflation, that's coming through the supply chain right now.

Jon, can you be a little more specific in terms of timeframe, what you're asking about?

Sure. I mean, over the next two or three years, it will be perfect if you can go into, how you expect your profitability to ramp especially as these new plants complete.

So, we expect margins to improve over time, as we increase capacity. The more scale we have, the better we can spread out those fixed costs. So, I think when you look at the out years as compared to the previous models that you've seen, there'll be a tremendous increase in profitability, really just driven by volume. In the near-term, I would expect less profit, less profitability at the bottom line than what was previously disclosed. Because in order to accelerate that growth, we're pulling in quite a bit of OpEx, mainly with new hires. We're hiring quite a bit of people this year that we didn't intend to prior to the announcement to double the size of the Greenfield plant.

Understood. That makes a lot of sense. And can you just comment on the spreads that you are making on your product these days. How you're pricing to customers just given the price of feedstocks the canola oil going up?

Yes, let me say one more thing in terms of, kind of longer-term before I address that one specifically. We are just getting started. And you've heard me say this before, probably whether the fossil fuel industry has been optimizing for 70-years. So we know, this is one of those things, you have to talk about known unknowns and all that. This is one of those things where we know we're going to be able to take costs out of this business as we grow, both on our CapEx per pound basis, and on a cost of goods sold basis. In this as we kind of look at that, in the next five to 10-years, we think we can easily take 25% out of those costs, versus what we're currently forecasting. And then as far as your question, Jon, about margins, that's a little more. In the short-term, canola oil is going up in price. About half of our current contracts have escalators in them that allow us to pass that on to the contracted customer. We put that language in every contract that we had that was multi year. So, in the one year contracts that we did, we didn't have that in there, but we had hedged. So we won't really see impacts from that canola margin or canola pricing increase until the later part of this year.

Got it. Thank you very much. And then just on the new expansion plans, $700 million, about half of that you already have on the balance sheet. How do you plan to finance the rest?

We're exploring every option available, and we'll get back to you on that. And go back to your last question to Jon, I would also just want to remind you that, we are not limited to using canola oil as a feedstock. And so we are also aggressively looking at alternatives, which we know, there are a lot of alternatives, but obviously, we're looking for economical, more economical alternatives, if you will. So that's an ongoing project.

Okay, great. Actually, if you don't mind, one more. Has there been any change in the competitive environment, not that you've shown you the world that you're sold out for the next two years, and maybe for the next four or five? Are there perhaps companies that can't get on your list at the moment, who are turning to other PHA players, and maybe willing to fund them to accelerate their growth over the next couple of years in order to get their hands on similar products?

Well, we're not aware of any other major brand owners that are doing that. I will say this, that we have not ever engaged with one of these major brand owners, and then had them go somewhere else. I think we're far enough ahead that they see the benefit of dealing with us now. And we're working really hard, which is one of the reasons why we announced doubling of the Greenfield, we're working really hard to make sure that we can satisfy all these customers that have kind of interested their future packaging to us. So that's the goal is to try to keep them all happy and keep adding customers in the fold. But we have not seen anything yet that would indicate that our lead is in jeopardy.

Got it. Thank you very much, and congrats again.

Thanks, Jon.

And our next question is from Laurence Alexander with Jefferies. Please proceed with your question.

Good afternoon. First, on the new expanded capacity targets. Do you already have an anchor tenant for the extra volume? Or to what degree is that capacity sold out, I mean under contract?

Yes. It's in the early years, I would say it's roughly 10% under contract warrants. But, we still have a lot of time to get to actual contracts. And so the answer is, yes, we have two new anchor tenants, which would be Mars and Bacardi. Mars and Bacardi were not contemplated in our financial models when we were marketing the pipe. And so those are new customers. We've also added a third brand, which we can't talk about, because they view it as a competitive advantage. So we really have three significant new customers in the pipeline from the financial model that we use to build the Greenfield plant, originally, the model for the plant. And while we don't have off-take agreements yet with those customers, we have forecasts and plans are in place.

And then, with respect to the State of Georgia, is the support from the State of Georgia is significant? And if so, is that factored into the 30% cash flow rate?

It is. We believe it is significant. It's valued in the 10s of millions of dollars, and it's not factored into the ROIC.

And then can you address sort of average selling prices? How they're doing now? And do you still expect them to be in roughly the 250 range or to what degree is these are moving?

Yes, the average selling price is pushing about 270 right now. So, I would say that it's been increasing slightly, over the last few months.

And then just the last one on my side. Can you address the criteria that you would have to do capacity project overseas? I noticed on Slide 14, you go from two green lines to three green lines to four green lines, and there's all sorts of interpretations for that. So just wondering how you think about geographic expansion or doing multiple projects in parallel?

Yes, so as you may have heard me say before Laurence, after we finish this -- by the time we finish completion of this first Greenfield project, we need to have the internal resources and competence built up to be able to build two plants at once. And one or both of those could be overseas. So, we're proceeding with that in mind. And when you see that the green lines on that slide, I guess it goes from two at once to three at once to four at once. It represents, our medium-term goal, if you will, to develop that competence and resources in house to build a build four plants at once.

Okay, great. Thank you.

And our next question is from Vincent Andrews with Morgan Stanley. Please proceed with your question.

Thank you. Good afternoon, everyone. I want to just dig in a little bit on the $700 million for the two Greenfields. If you could just sort of bridge us from I believe the original estimate was 285 for one. So I'm just curious what's changed in terms of the cost of each Greenfield? And, I thought maybe there might be some scale benefits of building two, rather than one. So maybe you could just help us understand what's happened to sort of the per unit costs of construction since your last update?

Yes. So really, it's three things, Vincent. The first is and again some of you will have heard me explain this in the past, but a refresher, that original estimate, we spent about $200,000 on it's been well over a year, since that was done. And now, since we closed on the SPAC deal and had cash, we've started a $13 million engineering project to finalize, not just the price quote, estimate, but the actual plants be constructed with. So that started in late December. And we just about a week and a half ago, we got a plus or minus 30% estimate. That estimate by I believe July will be done, will go to a plus or minus 20%, and before construction, it'll get down to a plus or minus 10% estimate. So, we're hoping to -- no guarantees, it could go the wrong direction, but we're hoping to be able to drive that cost lower over time with value engineering. So the three things that I would point to that are different. First of all, it's just maybe the level of the thoroughness of the estimate at this point, relative to the first one that was made is part of it. Secondly and we were surprised as some of the inflationary things that we saw both with the cost of steel, but with labor as well. And I think one of the things that's happening right now is, as people are -- as we see ourselves coming out of the pandemic, I think there is a lot of activity like this going on. And then thirdly, we've intentionally added some costs to the project where we can drive COGS lower, or drive expenses out. So, there's been some optimization and some efficiencies developed that will cost more money. But ultimately, you have a great return. And that's why when we look at the efficiencies that we're getting, between those things and doubling the size of the plant, that's why we're still reporting that we believe its 30% ROIC.

Okay. And just as a follow-up to that, is the timing of how long it will take to build the Greenfield? Is that within that sort of plus or minus 10% estimate? Or is that subject to change, as the engineering sort of work is completed in the coming months?

Yes. Right now, the timing is the same on a relative basis, but it's going to be -- the entire project is going to take longer than the three fermenter version, because of the way we're doing it. We're starting with three fermenters, initially. And then when those are complete, we'll turn to the next three. So the second-half will take longer to complete than originally proposed. So the entire project is a longer project now than what it was originally. Did I answer that question?

Yes, I understand. You're saying the first Greenfield can take as long as you previously thought. But now that you've added the second one, it obviously takes longer to do both. But the timing of constructing each project hasn't changed. Is that correct?

Yes, it's pretty much. That's correct, the way you said it. Although, we are thinking of it really as just one plant.

Sure.

So, it's not really Greenfield 1 and Greenfield 2, it's really just a Greenfield 1. And it's just going to have six fermenters.

Got you. And maybe just one last clarifier for me. Did you earlier say that, you have about 10% of the new Greenfield capacity contracted? Or is that not correct?

No, I said that.

Okay. All right. Thank you very much. I'll pass it on.

And our next question is from Jon Tanwanteng with CJS Securities. Please proceed with your question.

Hi. Thanks for the follow-up. So I just want to ask about the PLA business and what's your expectations for that this year? And how that tracks going forward as well?

Sure. So we had a really strange year, last year, on the PLA side of the business. We should just kind of call that the base business because, we are agnostic as far as the final formulation of a product. We're trying to solve customer problems. And if those formulations end up with all PHA all PLA or some combination in between, it doesn't really matter to us. But the base business is all PLA based and other biopolymers. So, we had a strange year last year when COVID came, our food service business just went away. And honestly we've had customers that have not ordered since before March. So some of that the folks that are in the restaurant business, some of that is still -- we're still seeing the effects of that. We made up for it last year in large part, because of one particularly large customer was concerned that what might happen if Danimer had a shut down due to COVID. And so they ordered in about 25% of their annual requirement as stocking inventory. And that had a significant positive impact last year. Now, unfortunately, we won't see that again this year. So it will -- we've got that in the history now, but it won't be in the growth numbers for this year. So, I think on a on a year-over-year basis, the PLA business is not going to look, it's not going to grow as rapidly as we're used to this year.

Okay. I got it. But still growing, just to clarify.

Yes.

Okay, great. Maybe just going back to the expansions, the 30% ROIC, it too sounds great. I was just wondering what the timeline is to actually reaching profitability, after you complete construction? What do you define that in terms of cash flow or EBITDA or net income? And just whatever you've been modeling to, is it six months? Is it nine months? How are you thinking about them, starting with the Kentucky and then going on to the Greenfield?

I don't know, if I know that answer off the top of my head, Jon. I do know that when we've modeled these projects that we hit breakeven when we are roughly a third of the stated capacity, when we get to that point we're breakeven.

Okay, got it. Okay, that's great. Thank you. And then finally, I just wanted to get the difference between the GAAP and the non-GAAP in terms of the other costs that though were expected to come through the stock comp fee, the depreciation? And just wondering what the difference is between GAAP and non-GAAP as we go forward?

John, you want to take that one?

As we go forward, we're planning on I guess reporting adjusted EBITDA and adjusted EBITDAR. And with adjusted EBITDA, we'll be adding back depreciation and amortization, taxes, stock based comp. And then, if there's some unusual one-time items, I think that in this year, for example, we'll have some expenses that we would term, one-time expenses that the company might incur, as we make the transition to becoming a public company. And that would be things like next year, we have to be compliant with the [Indiscernible]. So, we'll have some sort of rating this project that the company will have to undertake in the current year, that we think would be like an incremental expense. So, those are the types of things. And then we also have some rent expense that we've added back to give EBITDAR, that's primarily related to our facility in Kentucky. When we acquired that facility, we leased it back to a REIT, as an alternative to borrowing money. So, we'll also provide that metric. We'll look at our results with rent added back as well.

Okay. Got it. I just want to get a non-GAAP estimate for the OpEx this year.

No. For the OpEx over the non-GAAP estimate. Bear with us some seconds. Jon, I'll give you a little clarification on the PLA business this year. I would just make the point that we are still growing because we're in programs that are growing. But we don't forecast to add any pure straight PLA business this year. All our business this year that we're forecasting growth or new growth, new program growth would have PHA in it.

Okay. Got it. Thank you guys. If I can ask one more, just what is the share count at the end of Q1 that you're expecting to have?

Could you repeat that question, please?

What's expected diluted share count at the end of the first quarter?

So, I don't have the -- what I can tell you is that as of the day, we have about 88 million shares outstanding. And we also have about 11 million options outstanding to have a weighted average exercise price of about $13.94. In addition to the $16 million warrant that the company has outstanding as well.

Okay, great. Thank you.

And our next question is from Laurence Alexander with Jefferies. Please proceed with your question.

Just one last one, could you give some detail on cadence of customer inquiries, types of end markets? If you have any new end markets, or applications that are requiring you to develop new grades of PHA? Or if you're all just focusing on the same narrow, the same set of PHA grades?

Yes, great question, Laurence. So kind of depending on where, where you want to make the comparison. Our incoming leads are 2x to 3x over what they were prior to us making the announcement that we were going public. So, the number of incoming leads has picked up considerably. Our pipeline of big brand owners is as robust as it's ever been. And just to kind of give you the history there, we signed up Pepsi in Q4 of '16, we signed up Nestle in Q4 of '18, we signed up Bacardi in Q4 of '20, and then in Q1 of 2021, we signed up Mars. And I expect that kind of compression to continue going forward. As far as applications, there I would say the majority of the inquiries are usually responding to things where they've seen a press release or an article about another an existing product or a product that's being we're announcing is being developed. But a good number of them it's obviously smaller, relative basis. I don't want to put a percentage on it. But there are some new applications coming to light. There are inquiries coming and development in process on applications that don't even have anything to do with plastic. I can't talk about any of the specifics. But that's one of the things that we've always thought could happen and would happen. And we're excited to see that there are definitely some opportunities to expand outside of the 500 billion pound addressable market that we've talked about in the past.

Great. Thank you.

And our next question is from Vincent Andrews with Morgan Stanley. Please proceed with your question.

Thank you. I just wanted to follow up on the customer contracting for the Greenfield. And I get that there's this sort of chicken or an egg thing here where you can't contract a plant that you haven't announced yet. And now you've announced it, so presumably, the conversations are going to change and probably multiply. But I guess what I'm trying to understand is, if I'm looking at Slide 14, and it looks like you're going to break ground in early 2022, according to that. How much of the plant would you think you'll have contracted by the time you break ground? And how should we be thinking about that, maybe let's just start there.

Well, what I would like to see is to have a third of the whole plant contracted by the time we break ground on the second-half. But I'd like to -- that's a goal, not a hard forecast, but a goal.

So, just to be clear, a third of the overall Greenfield by the time you're doing the second three fermenters, or a third by the time you start the whole thing?

It'd be like as -- you could break it down into a sixth and a sixth. I'd like to have a sixth of it under contract by the beginning of next year, and then another six before the end of next year.

Okay. All right. Thanks very much.

We have reached the end of our question-and-answer session. And I will now turn the call over to Steven Croskrey for closing remarks.

Thank you. Thank you, everyone for joining us today. I'm proud of our team and excited for our future. I'd like to thank our shareholders for their tremendous support. We look forward to updating you on progress in the future. Have a good day.

This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.